ESSA Pharma Inc.
EPIX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.41 | 0.21 | 0.14 | 1.09 |
| FCF Yield | -8.47% | -14.52% | -35.81% | -8.26% |
| EV / EBITDA | -5.80 | -3.88 | -0.66 | -4.64 |
| Quality | ||||
| ROIC | -27.52% | -22.06% | -21.00% | -18.97% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.74 | 0.82 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -14.83% | 31.08% | -12.94% | -49.65% |
| Safety | ||||
| Net Debt / EBITDA | 3.63 | 1.27 | 1.62 | 3.75 |
| Interest Coverage | 0.00 | -4,628.94 | -2,524.48 | -1,661.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -9,674.40 | -6,247.87 | 328,632.66 | -4,754.47 |